Nano Pharmaceuticals
Market Cap
₹101 ₹101 Cr.
P/E
66.33
PEG = P/E ÷ 5yr Forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

Key Ratios

Debt to Equity
Debt to Equity
0.22
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
28.75 %
Institutions
Institutions
-
Market cap
Market cap
101 Cr
No. of Shareholders
No. of Shareholders
9,315
OPM (%)
OPM (%)
8.32 %
PE
PE
66.33
Prom Holding
Prom Holding
31.91 %
ROCE (%)
ROCE (%)
2.55
ROE (%)
ROE (%)
1.76
Sales
Sales
52.92 Cr
  • Veerhealth Care
  • Sotac Pharmaceutical
  • Denis Chem Lab
Last updated on 11 Sep 2026
  • Veerhealth Care makes Ayurvedic cosmetics, personal care and oral care. It contract-manufactures for brand owners and sells its own Ayuveer brand online.
  • Q1FY27 revenue reached ₹25.1Cr, up 388% YoY. EBITDA margin was 8.25% and PAT margin was 4.9%. The ramp is revenue-heavy, not margin-heavy.
  • Earnings come from repeat face-care orders for a 125-year-old FMCG group. Pharmacy, US e-commerce and marketplace clients add smaller repeat orders.
  • It holds USFDA clearance for OTC drug exports and in-house packaging through Veer Plast. Per management, few small-cap peers hold such clearance.
  • It is expanding plant capacity for contract-manufacturing and export scale. The ₹20.25Cr warrant programme would lift shares by ~50% on conversion.
  • Near-term earnings depend on the contract-manufacturing ramp. Management guides ₹105Cr total income in FY27 after three raises, with minimum PAT of ₹5-7Cr.
  • Two company secretaries left in nine months. The new secretary is the promoter-chairman's daughter.
  • Warrant conversion and FMCG repeats ongoing, 18-month window from Aug 2026
    full conversion provides ₹20.25Cr for expansion. Continued monthly repeats sustain the revenue base.
  • Test of ₹105Cr revenue pace Nov 2026
    revenue around ₹26Cr in the quarter keeps the full-year guide on pace. The margin shows if profit is catching up.
  • Indo-Canadian JV follow-on orders H2FY27
    contracted orders add ~₹3-4Cr of turnover in H2FY27 and ~₹10Cr in FY28.
  • Capacity expansion via warrant proceeds by 31 Oct 2027
    new plant capacity comes online to convert orders into revenue.
  • Russian oral-care export entry advanced stage, no timeline
    a first order would open a new export market.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
17
52W Range
High
52
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

9 Yes

Positive for this company

3 Neutral

Neutral for this company

4 No

Negative for this company

1 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Peer Comparison

Corporate Actions

Consolidated
DATE
DETAILS
Show More
Show Less
Show More
Show Less

FAQs on Veerhealth Care Ltd. Business

Veerhealth Care, originally incorporated as Niyati Leasing Limited in 1992, transitioned to the pharma sector in 2013, focusing on trading, manufacturing, and marketing research-based ayurvedic medicines.

Veerhealth Care major competitors are Denis Chem Lab, Sotac Pharmaceutical, Mercury Laboratories, Makers Laboratories, Pharmaids Pharma, Concord Drugs, Parmax Pharma.
Market Cap of Veerhealth Care is ₹100 Crs.
While the median market cap of its peers are ₹100 Crs.

Veerhealth Care seems to be less financially stable compared to its competitors.
Altman Z score of Veerhealth Care is 4.48 and is ranked 4 out of its 8 competitors.

Company Filing

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release Feb Apr Jun Aug Aug
Investor Presentation Feb Jun Aug Jun Sep
Conference Call
Conference Call SummaryCon Call Summary

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material